Hot Stocks to Watch: Enphase, Nio, and Intel
Last Friday, Enphase Energy (ENPH) jumped by 10.41% solely for one reason. The Fed Chair, Jerome Powell, suggested that the central bank is open to cutting rates by 25 bps in September.Lower interest rates would decrease the cost of borrowing to buy solar energy solutions. ENPH stock is in a yearlong downtrend that shows no signs of ending. The prospects worsened after the White House introduced policies that would reduce or eliminate federal clean energy tax credits. Expect the strong rally in stocks like SolarEdge (SEDC), Array Technologies (ARRY), and Sunrun (RUN) to eventually end.Nio (NIO) gained 31.8% last week to close at $6.34. Shares broke out after the firm unveiled an all-new ES8 model. The SUV has three rows, offered as six- and seven-seat variants. This is a premium vehicle, where consumers are unlikely to tell a difference between Lexus and Audi models.Intel (INTC) will settle in the $25 range with upside to the high $20s. After markets closed, the U.S. government said that it would take a 10% stake, or an $8.9 billion investment. It will pay $20.47 per share on 433.3 million shares. Trade INTC stock in the $5.00 range, but be wary of investing in it for the long term. The firm is far behind AMD in the CPU and server market. Its GPU and AI products are even further behind those of Nvidia (NVDA).
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


